Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
World game at war: why some European nations have threatened a World Cup boycott 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
YARDLEY, Pa., May 07, 2018 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2018, before market open on Monday, May 14, 2018.
Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including the retail availability of XHANCETM that commenced in early April 2018. The call is scheduled to start at 8:00 a.m. Eastern Time on Monday, May 14, 2018.
To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 21, 2018 by dialing (855) 859-2056 from the U.S. or +1 (404) 537-3406 from outside the U.S. and entering conference ID # 6968158. A simultaneous webcast of the call and presentation can be accessed by visiting the Investors section of Optinose’s website at www.optinose.com. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.
About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
[email protected]
267.521.0531
